You are here
Biogen Inc: Merck-Allergan Deal Could Send BIIB Stock Soaring Market Trends 

Biogen Inc: Merck-Allergan Deal Could Send BIIB Stock Soaring

Biogen Inc: Merck-Allergan Deal Could Send BIIB Stock Soaring Biogen Inc Has Something the Pharma Majors Want Biogen Inc (NASDAQ:BIIB) lost some 10% in one trading day last June. In fact, Biogen stock dropped to its lowest price of the year—$224.60 on June 24. That happened as the company admitted that lab tests of its new multiple sclerosis–targeting drug, “Opicinumab,” failed. But such things happen in the world of biotech. In fact, Biogen stock has hit a new record high for 2016, gaining 10% in a single day as Merck…

Read More